Skip to content

San Diego, CA, April 15, 2024 – FlemingMartin is pleased to announce that Anaptys, a publicly traded clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, has hired Mike Walsh to be their Senior Director of Research Project Management.

Mike is a project management expert who began his career as a scientist at Bristol-Myers Squibb before transitioning to a role in portfolio and project management. Mike has expertise supporting projects in various stages of development ranging from post-discovery to commercial. After spending 12 years at BMS, he joined Forty Seven which was then acquired by Gilead. Most recently, as Gilead’s Director of PDM Product and Portfolio Strategy, Mike focused on various programs in biologics, inflammation, and oncology, leading key initiatives and serving as a member of the Biologics Site Leadership Team.

Mike earned his MBA from Syracuse University and he received both his Master of Science in Biochemistry and Molecular Cell Biology and his Bachelor of Science in Nutritional Sciences from Cornell University.

Anaptysbio Logo 2 1Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. It is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease. In addition, Anaptys has developed two cytokine antagonists available for out-licensing for the treatment of generalized pustular psoriasis, or GPP, and etokimab, for the treatment of respiratory disorders. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology.

Fleming Martin Color Logo Medium 72 PpiFlemingMartin is a leading retained executive search firm that recruits exceptional executive talent for life sciences and technology companies nationwide. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.